Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. - Wikidata - awgldk - TriplyDB

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

http://www.wikidata.org/entity/Q48419903

about

Advances in rheumatology: new targeted therapeutics TNF-alpha inhibitors for ankylosing spondylitis Adverse effects of biologics: a network meta-analysis and Cochrane overview 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis Old and new treatment targets in axial spondyloarthritis Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis Golimumab for the treatment of ulcerative colitis Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis.Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.Report of 12 cases of ankylosing spondylitis patients treated with Tripterygium wilfordii Golimumab.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions Advances in managing ankylosing spondylitis Spondyloarthritides: evolving therapies Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.Biologic therapy for autoimmune diseases: an update.Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.Predicting the outcome of ankylosing spondylitis therapy Safety and clinical efficacy of golimumab in the treatment of arthritides.Management of arthropathy in inflammatory bowel diseases.Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab.Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.Juvenile spondyloarthritis treatment recommendations Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.

P2860

Q21093257-ABD929D5-3C24-49E3-A65E-56D74A924C71 Q24186462-FEE0A1FD-7573-48EE-8CCE-A01F6D6BA88A Q24234197-85BF9A98-C48B-4A48-B669-53C250CE4119 Q24603648-86E00368-119D-432F-8AF1-C4ACDE7BDA0F Q26738520-BC43781F-7A33-47F7-8F33-6583EEADB9E7 Q26741170-6746FE92-B958-4FFD-ABB9-4FD53C24C7C5 Q26764820-0836A2B7-98EB-4C46-8022-6C4C27B7FC3C Q26777906-49D0517C-DCBC-4E6F-A5BD-BBF316621593 Q26828622-2014A3A2-473E-4054-AD00-22E4B92E8ADD Q28236322-D6BC0EFC-E51E-4C59-B2EB-DB5FBB346931 Q30239856-18C7F546-BF1D-4D83-9A69-7FC6840086D0 Q30240183-BA2326B8-9813-48B2-818B-31263F742AC7 Q30240212-E81F4EE9-38E6-4451-8689-76FB28AE6761 Q30717002-5008EA4E-3258-4E75-80F3-46E0E7E69D46 Q30750448-BAC05D78-1B81-4207-B939-CAAB596386F4 Q31039549-CCC8C274-AAC7-4ACA-83CE-E3FC612F4D2A Q33833623-F248566D-C0C6-4809-A0F2-9FA0EA586A69 Q33973884-912A2B90-6F86-45A5-87FA-E76A8B405FBE Q34014598-E3EFE7AB-5F41-44C2-B150-183B4D53221D Q34092224-AA9D4A1C-DE01-4EE8-84D9-A8C6A58431D3 Q34110768-86BC8AC4-E70A-4FA1-A9DD-ED2E48A480F7 Q34201927-79DD9EE1-DA92-47A1-9A7F-A16CBC1EF206 Q34613907-78471BF4-9587-4F4E-8CE1-86B09A91A0C2 Q34620355-F871FF4D-E26D-4333-92A0-24D97A5ECCF9 Q34655597-9C0E6DCB-FD6E-44F0-BF38-BD2FFC772D43 Q34669637-AA077F3B-E16A-4120-96AB-2A2FA2E85BDE Q34728162-AD224E7C-8F49-4785-857C-992D19014C4B Q34803148-C9D66803-6DCF-448A-AB7E-2FB175531B6D Q34894874-6D8A21F6-BDCC-468E-B370-2B2EEE2511ED Q34905433-BF41CF30-2BDC-489F-90A6-35543CCDD411 Q35026454-A9D42F84-4C97-45F1-9D9A-BC808CF82B7A Q35091366-DFF7291A-D4C4-42E8-AEBD-C60DDA149CDB Q35608168-7FE5CAAB-9410-4529-AD2E-4ED020A1A776 Q35759171-77F65B8D-9DBF-4DCC-B88A-288806F95726 Q35896663-DBAB3686-36C6-41BC-948D-8AB792F83C3C Q35896670-8C7E9411-901A-4E1D-8470-A9E665B306ED Q36004879-7B390D83-0228-44A7-ADE8-890BAB356A98 Q36020178-9D4750B2-9C48-4C76-87C3-780AF9C9184E Q36059338-42EC8FDB-6CD1-4799-BCC1-F20A0C5F7F7D Q36157440-680DCB92-C980-48C9-9AAF-42E3E77ACA36

P2860

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

http://www.wikidata.org/entity/Q48419903

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Efficacy and safety of golimum ...... o-controlled, phase III trial.

@en

Efficacy and safety of golimum ...... o-controlled, phase III trial.

@nl

type

label

Efficacy and safety of golimum ...... o-controlled, phase III trial.

@en

Efficacy and safety of golimum ...... o-controlled, phase III trial.

@nl

prefLabel

Efficacy and safety of golimum ...... o-controlled, phase III trial.

@en

Efficacy and safety of golimum ...... o-controlled, phase III trial.

@nl

P1433

Q48419903-F5AA49D4-F801-49A1-A976-29D01C6BDBC7

P1476

Q48419903-688FADF3-EB81-4288-9ABD-46D4C71C68B3

P2093

Q48419903-1849E7D8-B688-4AD9-98E5-299CA1C13E5B

Q48419903-1B62C8BC-B925-4DBA-94B3-73EA1E0ED547

Q48419903-21EAFAEE-EE4A-414F-89AF-5842BE359770

Q48419903-5AE0B703-598C-4593-B6E2-188B79DA57AA

Q48419903-672B68C4-3200-48AD-BD5F-BF0953099DA3

Q48419903-7F510AB1-7C04-47FA-A882-EC88DF2614C5

Q48419903-995D3310-1A5D-4521-816B-86487D1236CE

Q48419903-A8AA929F-FFEF-48EE-96C3-6DE4FB47034E

Q48419903-BAB7D82B-8FF7-4BD9-8569-B5B1D381B8A7

Q48419903-BE5EF36F-343C-4F9B-9F1D-9CDDD6EA4674

P304

Q48419903-4AA27EFC-866A-4355-BAFA-D819C0EB7025

P31

Q48419903-8AFDAC60-A878-48F4-B381-7E9A0D5320B6

P356

Q48419903-0F9C2B36-33B2-4AA1-87F8-ADA0C951E9D1

P433

Q48419903-1AC61AFE-ABCF-411B-B402-0874F735F3F5

P478

Q48419903-4B2B57C9-4CCC-4C3C-A0F1-3B312614FEB6

P50

Q48419903-33A277A6-DDBE-4DE0-9279-9F550A5677CA

P577

Q48419903-BA34B74A-5799-4E63-8510-DB7F698B4D18

P5875

Q48419903-114CAF9F-B14F-410D-864D-BDB071A5E857

P698

Q48419903-A22AD264-1668-43A6-9819-8A987E82EF06

P921

Q48419903-414C6A31-EA20-4974-95ED-DAFE45E1E4AC

Q48419903-A3E54E0A-45B2-46AF-9213-F0D4F23AAF89

Q48419903-C01C2A75-0E25-4928-9045-22BE0E4183D6

P356

P1433

Arthritis & Rheumatology

P1476

Efficacy and safety of golimum ...... o-controlled, phase III trial.

@en

P2093

Anna Beutler

http://www.w3.org/2001/XMLSchema#string

Benjamin Hsu

http://www.w3.org/2001/XMLSchema#string

Joachim Sieper

http://www.w3.org/2001/XMLSchema#string

John C Davis

http://www.w3.org/2001/XMLSchema#string

John Han

http://www.w3.org/2001/XMLSchema#string

Jürgen Braun

http://www.w3.org/2001/XMLSchema#string

Laura Diekman

http://www.w3.org/2001/XMLSchema#string

Michael Mack

http://www.w3.org/2001/XMLSchema#string

Robert D Inman

http://www.w3.org/2001/XMLSchema#string

Sudha Visvanathan

http://www.w3.org/2001/XMLSchema#string

P304

3402-3412

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.23969

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Désirée van der Heijde

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23442864

http://www.w3.org/2001/XMLSchema#string

P698

18975305

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial